228 Hematology Molecular Tumor Board (012722)
This monthly tumor board meeting will focus on cross collaborations between physicians from the hematopathology team, flow cytometry team, cytogenetic team, molecular pathologists as well as UTSW clinical faculty members in hematologic malignancies. Cases to be discussed will be submitted 1-2 weeks ahead of time in order to prepare bone marrow biopsy data, clinic pathologic and molecular data. We will be reviewing practice data and the impact of molecular testing on clinical decision making and presenting that to the group at the end of the year. This would highlight the importance of molecular testing but also the importance of a multidisciplinary tumor board to interpret the results in the most effective way. This meeting is tentatively scheduled to take place every 4th Thursday of each month (once/mo) for approximately 1 hour.
This activity is appropriate for Malignant hematology clinical faculty members, hematology oncology fellows, hematopathology residents and fellows, hematopathology faculty, and molecular pathology faculty.
(1) Discuss hematologic malignancies cases and current recommendations for aiding in clinical decision making.
(2) Recognize and discuss the complexity of molecular tumor testing.
(3) Identify and discuss how molecular testing can alter treatment decisions
(4) Determine clinically relevant molecular information to incorporate into best practices
- 1.00 AMA
- 1.00 Attendance